Literature DB >> 11939578

Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.

William D Campbell1, Eliada Lazoura, Noriko Okada, Hidechika Okada.   

Abstract

Pro-carboxypeptidase R (proCPR), also known as thrombin-activatable fibrinolysis inhibitor (TAFI), precursor of carboxypeptidase U and plasma carboxypeptidase B is present in plasma and following activation by thrombin/thrombomodulin and/or plasmin can remove arginine from the carboxyterminal of C3a and C5a. We have shown that this enzyme can remove terminal arginine from the C5a octapeptide much more efficiently than the classical anaphylatoxin inactivator, carboxypeptidase N (CPN). Since we have previously demonstrated that proCPR is significantly upregulated in the inflammatory state, this enzyme would appear to significantly contribute to the inactivation of C5a, the most potent of the complement derived anaphylatoxins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939578     DOI: 10.1111/j.1348-0421.2002.tb02669.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  54 in total

1.  Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system.

Authors:  Sara H Bengtson; Caroline Sandén; Matthias Mörgelin; Pauline F Marx; Anders I Olin; L M Fredrik Leeb-Lundberg; Joost C M Meijers; Heiko Herwald
Journal:  J Innate Immun       Date:  2008-07-12       Impact factor: 7.349

2.  Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.

Authors:  Tanya M Binette; Fletcher B Taylor; Glenn Peer; Laszlo Bajzar
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

3.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

Review 4.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Authors:  Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 6.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

7.  A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.

Authors:  Nobuaki Okumura; Tomohiko Koh; Yuichi Hasebe; Taiichiro Seki; Toyohiko Ariga
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

Review 8.  Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).

Authors:  Lawrence L K Leung; Timothy Myles; Toshihiko Nishimura; Jason J Song; William H Robinson
Journal:  Mol Immunol       Date:  2008-08-15       Impact factor: 4.407

9.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

10.  Inactivation of the complement anaphylatoxin C5a by secreted products of parasitic nematodes.

Authors:  Dominic Rees-Roberts; Lisa M Mullen; Kleoniki Gounaris; Murray E Selkirk
Journal:  Int J Parasitol       Date:  2009-10-27       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.